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The cancer genome can elicit sensitivity to certain drugs not specifically designed to target the underlying genetic aberrations. To this end, genomic markers of drug sensitivity have been systematically assessed in cancer cell lines \[[@CR1], [@CR2]\]. Ideally, these markers can identify patients who may better benefit from a certain antineoplastic drug \[[@CR3], [@CR4]\]. In contrast to the increasing availability of data about genomics of drug sensitivity in vitro \[[@CR5]\], the association with improved patient survival is so far limited to few clinical cases, e.g., exceptional responses to everolimus in bladder cancers with *TSC1* mutations \[[@CR6]\].

Here, we sought to systematically assess if the chances of overall survival in patients with a certain cancer type and treated with a given antineoplastic drug correlate with the presence of a certain genetic mutation in the tumor. The examined cohort comprised 3105 patients, spanning 12 cancer types (with 81--731 samples for each cancer type). Collectively, 21 antineoplastic drugs were administered each in at least 20 patients (median 82; IQR 29--150). Six cancer-associated mutations were detected in at least 20 patients in this cohort: V600E in *BRAF* (*n* = 29), R132H in *IDH1* (*n* = 108), G12V in *KRAS* (*n* = 49), H1047R in *PIK3CA* (*n* = 89), R175H in *TP53* (*n* = 45), and V777 deletion in *ZFHX3* (*n* = 22). After binning samples by cancer type, out of 1512 potential associations, 9 associations between overall survival, drug treatment, and tumor mutation had sufficient sample size for each covariate and were hereby tested. The hazard ratio (HR) for each interaction between drug treatment and tumor mutation in a cancer type was estimated in a multivariate analysis using a nested Cox proportional hazard regression model. We adopted a likelihood ratio test to test whether there is a significant effect of the interaction on overall survival on top of the tumor mutation and administered drug alone (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

We observed a significant effect only in one scenario, the interaction between temozolomide (TMZ) and R132H mutations in *IDH1* on the overall survival of lower-grade glioma (LGG) (likelihood ratio test *p* = 0.026). This test suggests that the correlation with survival is specific to the interaction between TMZ and R132H mutations in *IDH1* and not associated with the drug treatment or the mutation per se, as demonstrated by the Kaplan-Meier curves generated for patients stratified upon these features (log-rank test *p* = 0.047, Fig. [1](#Fig1){ref-type="fig"}). The median overall survival for patients with the interaction was 95 months (95 % CI, 63---N.E.) and for patients without the interaction was 62 months (95 % CI, 49--87).Fig. 1Kaplan-Meier survival plots for patients with or without an interaction between temozolomide and R132H mutations in *IDH1* in lower-grade glioma

We detected a significant prognostic value for the interaction using a univariate Cox proportional hazard regression model (*p* = 0.016, Table [1](#Tab1){ref-type="table"}). However, the interaction violated the proportional hazard assumption and showed a time-dependent effect. The univariate analysis was also run on validated prognostic factors in LGG \[[@CR7]\] and additional clinical features (Table [1](#Tab1){ref-type="table"}). A multivariate analysis based on significant factors from the univariate analysis and including a time-dependent effect for the interaction revealed an independent positive correlation between the interaction and overall survival (HR 0.09, 95 % CI 0.01--0.58, *p* = 0.012), which tends to diminish over time (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Table 1Hazard ratio (HR) for clinical factors in the overall survival of lower-grade gliomaFactors*N* \[*n* death\]HRUnivariateMultivariate95 % CI*p*HR95 % CI*p*Age2611.071.05--1.095e^−10^1.071.05--1.096e^−9^Gender Female117 \[30\]1 Male144 \[33\]0.880.54--1.450.620Temozolomide No41 \[24\]1 Yes220 \[39\]0.800.47--1.350.398R132H in *IDH1* Undetected166 \[45\]1 Detected95 \[18\]0.740.43--1.290.292Interaction drug-mutation Absent181 \[57\]11 Present80 \[6\]0.350.15--0.830.0160.090.01--0.580.012Histology Astrocytoma107 \[27\]1 Oligoastrocytoma/oligodendroglioma154 \[36\]0.670.40--1.100.112Tumor grade Grade II77 \[18\]11 Grade III184 \[45\]2.061.18--3.610.0111.520.85--2.710.159Laterality N.A.1 Left131 \[28\]1 Midline5 \[1\]0.340.04--2.640.304 Right123 \[33\]0.820.49--1.370.443Tumor site N.A./other31 Supratentorial, frontal lobe160 \[36\]1 Supratentorial, occipital lobe5 \[1\]0.710.10--5.200.736 Supratentorial, parietal lobe23 \[4\]0.840.30--2.380.748 Supratentorial, temporal lobe70 \[21\]1.861.08--3.220.0261.220.70--2.110.481Symptoms at diagnosis N.A./other19 Headaches62 \[18\]1 Mental status changes22 \[8\]1.840.80--4.270.153 Motor/movement changes22 \[6\]1.200.47--3.060.698 Seizures119 \[23\]0.580.31--1.080.087 Sensory changes11 \[2\]1.070.24--4.660.929 Visual changes6 \[2\]0.690.16--2.980.617

In conclusion, we identified one genomic marker of drug sensitivity that was associated with better survival in patients, in contrast to patients treated with the same drug but with no detected mutation or vice versa. Indeed, mutations in *IDH1* were previously implicated with good prognosis in brain tumors treated with TMZ \[[@CR8], [@CR9]\]. Our results independently validate these findings and further extend the reach of this correlation beyond some previous limitations \[[@CR10]\]. First and foremost, the cohort size allowed discerning that an increase in patient survival was exquisitely associated with the interaction between *IDH1* mutations and TMZ, suggestive of a synergy between treatment and tumor genomics. Second, it specifically correlated with R132H mutations. Finally, we recovered a negative time-dependent effect of the interaction, which is reminiscent of emergence of drug resistance and in line with the genetic evolution of lower-grade glioma attributed to TMZ treatment \[[@CR11]\].
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